Pharmaceutical company Janssen Pharmaceutical Companies reported on Tuesday the receipt of US Food and Drug Administration (FDA) Breakthrough Therapy Designation for its investigational prophylactic vaccine for the prevention of respiratory syncytial virus (RSV)-mediated lower respiratory tract disease in adults.
The company added that the investigational prophylactic vaccine is currently in a Phase 2b proof of concept study to investigate the safety and efficacy of the vaccine against RSV in adults aged 65 years and older.
Older adults aged 60 years or older are among the populations at highest risk of developing RSV, a highly-contagious, potentially life-threatening respiratory infection. RSV is a leading cause of bronchitis and pneumonia, affecting more than 64m people each year worldwide.
This US FDA breakthrough therapy designation was based on clinical data from the company's prophylactic RSV senior vaccine that may demonstrate substantial improvement compared to available standard of care on a clinically significant endpoint(s).2
Following the US FDA Breakthrough Therapy Designation, the company's prophylactic RSV senior vaccine candidate is now eligible for all associated FDA features.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib